Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ImmuCell Corporation (Nasdaq: ICCC) announced preliminary sales results for Q1 2023, reporting $3.45 million, a decline of 43% from $6.00 million in Q1 2022. The decrease is attributed to a production slowdown due to previously disclosed contamination issues. The backlog of orders increased significantly to $7.5 million from $2.5 million at the end of 2022. Efforts during the slowdown included process improvements and complete sanitization of production facilities. Quality control tests have shown an 82% pass rate for incoming milk batches. The company is preparing for a third submission to the FDA for the Re-Tain® product by end of April 2023, with a six-month review period expected. A conference call is scheduled for May 12, 2023, to discuss full financial results.
ImmuCell Corporation (Nasdaq: ICCC) reported its unaudited financial results for the year ended December 31, 2022, showing a net loss of $2.5 million compared to a net loss of $78,000 in 2021. The gross margin fell to 41% from 45% due to contamination issues in production. The company faced production slowdowns and increasing backlogs, which reached $2.5 million. Cash reserves decreased to $5.8 million, down from $10.2 million in the prior year. Despite setbacks, ImmuCell is focused on expanding production capacity while preparing to resubmit critical FDA documentation for its Re-Tain® product, which addresses significant losses from subclinical mastitis in the dairy industry.
ImmuCell Corporation (Nasdaq: ICCC) has announced its upcoming unaudited financial results for the year ending December 31, 2022, to be released after the market closes on February 21, 2023. A conference call will follow on February 22, 2023, at 9:00 AM ET for discussing these results. Investors can participate by calling (844) 855-9502 or (412) 317-5499. The Company also plans to file its Annual Report on Form 10-K around March 29, 2023, and will update its Corporate Presentation on its website.
ImmuCell is known for products that enhance cattle health, including First Defense® and the developing Re-Tain® treatment.
ImmuCell Corporation (Nasdaq: ICCC) announced its preliminary, unaudited sales results for 2022, showing total sales of $18.57 million, down 3.5% from $19.24 million in 2021. Q4 sales were $3.91 million, a 28.2% decline compared to $5.44 million in Q4 2021. Notably, the company reported a backlog of $2.5 million, significantly up from $205,000 in Q3 2022. Despite production delays, the company aims to obtain regulatory approval for its Re-Tain product in 2023.